HBV-associated hepatocellular carcinomas inhibit antitumor CD8⁺ T cell via the long noncoding RNA HDAC2-AS2

Nature Communications, 28 February, 2025, DOI：https://doi.org/10.1038/s41467-025-57367-8

HBV-associated hepatocellular carcinomas inhibit antitumor CD8⁺ T cell via the long noncoding RNA HDAC2-AS2

Yanan Gao, Zhenxing Zhang, Xuetao Huang, Maojun You, Chengzhi Du, Nan Li, Yajing Hao, Kang Wang, Xiang Ding, Fuquan Yang, Shu-qun Cheng, Jianjun Luo, Runsheng Chen & Pengyuan Yang

Abstract

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. Extracellular vesicles (EV) are critical mediators of intercellular communication within the tumor microenvironment, and cancer-cell-secreted EVs often facilitate cancer progression. Here we show that in HBV-associated HCC, tumor-cell-derived EVs contain a TGFβ-inducible long noncoding RNA, termed HDAC2-AS2. EVs enriched with HDAC2-AS2 facilitate cancer progression by suppressing cytotoxicity of intra-tumor CD8⁺ T cells. Mechanistically, in activated cytotoxic CD8⁺ T cells, translocation of the transcription factor cyclin-dependent kinase 9 (CDK9), to the cytoplasm is critical for functional integrity. HDAC2-AS2 targets and blocks cytosolic CDK9, and this results in exhaustion of PD-1⁺CD8⁺ T cells and suppression of IFN-γ⁺CD8⁺ T cell cytotoxicity. Notably, we demonstrate that low CDK9 and high HDAC2-AS2 expressions are associated with poor survival of HCC, which can be rescued by anti-PD-1 therapy. These findings emphasize the significance of tumor-derived EVs in suppressing antitumor CD8⁺ T cell immunity to promote tumorigenesis, and highlight extracellular HDAC2-AS2 as a promising biomarker and therapeutic target for HCC.

文章链接：https://www.nature.com/articles/s41467-025-57367-8

相关报道：//www.wyreworks.com/jz/zxdt/202503/t20250305_7548100.html